Developing Countries Vaccine Manufacturers Network (DCVMN International)

📣 How Can a Participant-Centered Approach Transform Vaccine Trials? Join us on March 6 at 14:00 CET for a new DCVMN webinar in collaboration with VaxTRIALS, part of Emmes Group exploring how prioritizing participants leads to better enrollment, visit compliance, and retention in vaccine studies. 𝗪𝗵𝘆 𝗮𝘁𝘁𝗲𝗻𝗱? Vaccine trials depend on engaged participants, yet barriers like mistrust, logistical challenges, and lack of support can impact study success. This session will showcase real-world evidence on how addressing these issues leads to improved trial outcomes. We will explore the VaxTRIALS Recruitment & Adherence Model, designed to optimize participant engagement. Featuring industry experts & case studies from Latin America, this webinar will cover: 🔶 The impact of a participant-centered approach on vaccine trials 🔶 Key metrics & success factors from real-world studies 🔶 Lessons from LatAm case studies on effective engagement strategies Register now ➡️https://lnkd.in/eee6ej3Y #VaccineTrials #ClinicalResearch #PatientEngagement #Biopharma #DCVMN #VaxTRIALS #ClinicalTrials #Vaccines

🔔 The DCVMN webinar held in collaboration with Merck Group is happening this Tuesday, February 25, at 11 AM CET! If you work in vaccine development, quality control, or regulatory affairs, this session is for you. Viral vaccines make up 70-80% of global immunizations, yet their CMC QC testing comes with unique challenges: test interference, neutralizing antisera availability, and diverse cell substrates. This webinar will explore how Next-Generation Sequencing (NGS) and degenerate PCR-based technologies can help overcome these hurdles and improve vaccine quality and safety. Do not miss this chance to gain valuable insights from industry experts! Register now ➡️https://lnkd.in/eufeiScD #Vaccines #Biopharma #QualityControl #ViralVaccines #NGS #PCR #Biotech #DCVMN #Merck

𝗢𝗽𝘁𝗶𝗺𝗶𝘇𝗶𝗻𝗴 𝗤𝗖 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗳𝗼𝗿 𝗩𝗶𝗿𝗮𝗹 𝗩𝗮𝗰𝗰𝗶𝗻𝗲𝘀: 𝗢𝘃𝗲𝗿𝗰𝗼𝗺𝗶𝗻𝗴 𝗞𝗲𝘆 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 Join us on February 25 at 11 AM CET for an insightful DCVMN webinar in collaboration with Merck Group on advancing Quality Control (QC) testing for viral vaccines. With viral vaccines comprising 70-80% of global immunizations, ensuring their quality and safety is critical, but QC testing comes with unique challenges, including test interference, neutralizing antisera availability, and diverse cell substrates. This session will explore Next-Generation Sequencing (NGS) and degenerate PCR-based detection platforms as powerful tools to enhance Chemistry, Manufacturing, and Controls QC testing, supported by regulatory guidance. What you will learn: 🔶 Key QC tests in viral vaccine production 🔶 Challenges with less common production cells and virus-containing test samples 🔶 How advanced molecular methods can improve testing accuracy and efficiency Register here ➡️ https://lnkd.in/eufeiScD #Vaccines #Biopharma #QualityControl #ViralVaccines #NGS #PCR #Biotechnology #DCVMN #Merck

🌟 Celebrating a Milestone: WHO Prequalification for FLU-M Influenza Vaccine!   We are thrilled to share an incredible achievement from two of our esteemed members, SPbSRIVS (Saint Petersburg Institute of Vaccines and Serums FMBA of Russia) and Instituto Latinoamericano de Biotecnología MECHNIKOV (Nicaragua). Their work has resulted in the successful World Health Organization prequalification of the FLU-M influenza vaccine, marking a monumental milestone in the fight against influenza as it is now one of only two WHO-prequalified influenza vaccines in the Latin America and Caribbean region!   FLU-M is now the first Russian influenza vaccine to receive WHO prequalification and is officially recommended for purchase by UN agencies such as the Pan American Health Organization Revolving Fund and UNICEF.   FLU-M, a trivalent inactivated split vaccine, is designed to prevent influenza without the use of adjuvants. The rigorous WHO prequalification process reaffirmed its high quality, safety, and efficacy, meeting the most stringent international standards. This thorough assessment resulted in FLU-M joining the ranks of other globally recognized influenza vaccines, including Vaxigrip (Sanofi), GC Flu (GC Biopharma (GC녹십자)) and Serinflu (Abbott Biologicals).   At DCVMN, we are proud to celebrate this remarkable achievement and applaud SPbSRIVS and Instituto MECHNIKOV, S.A. for their dedication to advancing public health! https://lnkd.in/ecs2Gt62   #VaccinesWork #GlobalHealth #InfluenzaVaccine #Innovation #DCVMN #WHO #PublicHealth

DCVMN International is proud to share a remarkable achievement by one of our member companies, SINERGIUM Biotech in collaboration with the Pan American Health Organization (PAHO), the Government of Argentina and Pfizer, in strengthening vaccine production and access in Latin America and the Caribbean.   A groundbreaking partnership has been announced between the PAHO, the Government of Argentina, Pfizer, and Sinergium Biotech to facilitate local production and regional access to the 20-valent pneumococcal conjugate vaccine (PCV20) reducing the burden on vulnerable populations. This collaboration marks the first use of PAHO’s pooled procurement mechanism, the Regional Fund for Vaccines, to leverage a technology transfer agreement. It underscores the critical role of regional markets in making local vaccine production sustainable.   As a Network dedicated to empowering vaccine manufacturers in developing countries, DCVMN remains committed to serving as a bridge, supporting our members in forging partnerships like these with other manufacturers, governments, and international organizations. These collaborations are essential to achieving equitable access to life-saving vaccines, ensuring health security, and building robust regional production capacities that benefit populations worldwide.   Congratulations to Sinergium Biotech,  PAHO, the Government of Argentina and Pfizer in this remarkable achievement! This success sets an inspiring precedent for future initiatives to strengthen vaccine self-reliance and access across the globe.   #VaccineAccess #RegionalProduction #PublicHealth #DCVMN #Partnerships #Innovation

This Thursday, January 23rd, at 11:00 CET, join us and Univercells Technologies by Donaldson to explore cutting-edge solutions for overcoming key challenges in vaccine production. Vaccine manufacturing often faces hurdles like complex processes, long development times, and scalability issues. This webinar will shed light on how innovative fixed-bed bioreactor technologies and integrated manufacturing systems are addressing these challenges. This session is particularly relevant for vaccine manufacturers in the DCVMN network, offering practical insights to strengthen production capacity and ensure the timely delivery of effective vaccines. Reserve your spot today and be part of the discussion on the future of vaccine manufacturing. Register here ➡️ https://lnkd.in/e39SJjQ9 We look forward to seeing you there! #DCVMN #VaccineManufacturing #Innovation #GlobalHealth

We are happy to announce DCVMN Pharmacovigilance Working Group’s latest article, "𝗔𝗰𝘁𝗶𝘃𝗲 𝘃𝗮𝗰𝗰𝗶𝗻𝗲 𝘀𝗮𝗳𝗲𝘁𝘆 𝘀𝘂𝗿𝘃𝗲𝗶𝗹𝗹𝗮𝗻𝗰𝗲 𝗶𝗻 𝗹𝗼𝘄- 𝗮𝗻𝗱 𝗺𝗶𝗱𝗱𝗹𝗲-𝗶𝗻𝗰𝗼𝗺𝗲 𝗰𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀: 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗳𝗼𝗿 𝘃𝗮𝗰𝗰𝗶𝗻𝗲 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗲𝗿𝘀 𝗳𝗿𝗼𝗺 𝗲𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝗰𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀," in the journal 𝘝𝘢𝘤𝘤𝘪𝘯𝘦. This publication marks a significant step in the Working Group’s efforts to support emerging manufacturers in implementing robust pharmacovigilance (PV) systems. Read the full article here: https://lnkd.in/e9f6yCjR The article highlights the challenges faced by manufacturers in LMICs in adopting Active Vaccine Safety Surveillance (AVSS), a critical area where practices are not yet well established. The rapid development of COVID-19 vaccines emphasized the importance of Risk Management Plans (RMPs) for novel vaccines, leading DCVMN to launch hands-on projects that guided member companies in preparing RMPs aligned with international guidelines. Building on this foundation, the group initiated a “learn-by-doing” AVSS project, empowering representatives from member companies to deepen their understanding of AVSS concepts, methodologies, and barriers while addressing growing regulatory requirements and WHO prequalification standards. This achievement reflects our collective commitment to fostering education, collaboration, and capacity-building among DCVMN members, strengthening PV systems in LMICs, and ensuring vaccine safety and efficacy. By advancing these efforts, we aim to bolster public confidence in immunization programs worldwide. 💡 We invite you to explore the publication and join us in congratulating the great work done by the Pharmacovigilance Working Group in advancing vaccine safety surveillance for DCVMs. Together, we can make vaccines safer and more accessible for all! #DCVMN #VaccineSafety #Pharmacovigilance #GlobalHealth #VaccineManufacturing

Ensuring the timely delivery of effective viral vaccines is a critical step in improving global public health. Traditional manufacturing methods, however, often face challenges like complex processes, lengthy development times, and limited scalability. On January 23rd at 11:00 CET, we are hosting a webinar in collaboration with Univercells Technologies by Donaldson focused on solutions to these challenges. We will dive into how structured fixed-bed bioreactors and integrated manufacturing technologies are transforming vaccine production by: 🔶 Supporting high cell densities and improved productivity 🔶 Simplifying scale-up with reproducible results 🔶 Reducing manufacturing footprint and cost per dose This session will provide insights into practical innovations that can accelerate vaccine development and enhance scalability, which are key priorities for our network in strengthening global vaccine production capacity. Register now ➡️ https://lnkd.in/e39SJjQ9 Let’s connect and discuss how these advancements can benefit vaccine manufacturers worldwide. #DCVMN #Webinar #VaccineProduction #BiotechInnovation #GlobalHealth

𝗝𝗼𝗶𝗻 𝗮 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽 𝗼𝗻 𝗧𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻𝗶𝗻𝗴 𝗗𝗧𝘄𝗣 𝗩𝗮𝗰𝗰𝗶𝗻𝗲𝘀 𝘁𝗼 𝗔𝗻𝗶𝗺𝗮𝗹-𝗙𝗿𝗲𝗲 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 DCVMN is pleased to share details about an upcoming two-day online workshop organized by Animal-Free Safety Assessment Collaboration and Humane Society International (HSI), focusing on “𝗧𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻𝗶𝗻𝗴 𝗗𝗧𝘄𝗣-𝗖𝗼𝗻𝘁𝗮𝗶𝗻𝗶𝗻𝗴 𝗩𝗮𝗰𝗰𝗶𝗻𝗲𝘀 𝘁𝗼 𝗔𝗻𝗶𝗺𝗮𝗹-𝗙𝗿𝗲𝗲 𝗕𝗮𝘁𝗰𝗵 𝗥𝗲𝗹𝗲𝗮𝘀𝗲 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆: 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀 𝗳𝗼𝗿 𝗜𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻.” 🗓️ 𝗪𝗵𝗲𝗻? January 29th and 30th, 2025 🕚 𝗧𝗶𝗺𝗲: 11:00 AM – 2:00 PM CET (Central European Time) 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: 📌 Day 1 (January 29): Safety Testing Discussions 📌 Day 2 (January 30): Potency Testing Opportunities, including a specific discussion on the whole-cell Pertussis in vitro potency test This event is part of the HSI Project, supported by the Bill & Melinda Gates Foundation, aimed at accelerating the adoption of animal-free batch-release testing for human vaccines. 𝗪𝗵𝘆 𝗔𝘁𝘁𝗲𝗻𝗱? 🔸Gain insights into cutting-edge non-animal testing strategies for DTwP-containing vaccines. 🔹Connect with global experts, industry peers, and regulatory authorities. 🔸Share knowledge, experiences, and strategies to overcome challenges in implementing in vitro testing methods. 🔹Explore steps needed to update local regulations, pharmacopeias, and guidance. ➡️ Register and view the full agenda here: https://lnkd.in/gbjh-jNm This workshop is a fantastic opportunity for our network to stay at the forefront of innovation and collaboration in vaccine testing strategies. We encourage all interested stakeholders to participate and contribute to this critical conversation. #DCVMN #VaccineTesting #NonAnimalTesting #DTwP #GlobalCollaboration #Innovation

🚨We are Hiring! The DCVMN International is seeking a talented and motivated professional to join our team as Assistant Manager – Training Administration & Event Management in Gurugram, India. This full-time role is an exciting opportunity to contribute to global public health by coordinating impactful training programs and events that build the capacity and capabilities of vaccine manufacturers worldwide. Join us in driving initiatives that ensure safe, effective, and accessible vaccines for all. Let’s work together to build a healthier, more equitable world! #Hiring #PublicHealth #TrainingManagement #EventManagement #CapacityBuilding #VaccineManufacturing #GlobalHealth #DCVMN #CareerOpportunity